.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights

EP. 1: New OS Data in Treatment for Nonmetastatic CRPC

November 14th 2019

EP. 2: Apalutamide in Treating Nonmetastatic CRPC

November 14th 2019

EP. 3: The SPARTAN Trial Interim Analysis

November 14th 2019

EP. 4: The PROSPER and ARAMIS Trials in CRPC

November 14th 2019

EP. 5: The Impact of Recently Approved AR-Targeted Therapy

November 14th 2019

EP. 6: The Future of Nonmetastatic CRPC Management

November 14th 2019

EP. 7: The STAMPEDE Trial Long Term Follow-Up Data

November 14th 2019

EP. 8: The Approval of Apalutamide for Metastatic CSPC

November 14th 2019

EP. 9: The Role of Enzalutamide in Treating Metastatic CSPC

November 14th 2019

EP. 10: Metastatic CSPC: Toxicity Management & Future Treatment

November 14th 2019